---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-002744"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2025-03-14T23:59:59+00:00"
generated_at: "2026-05-24T18:36:43.380214+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Zomedica reports record Q4 revenue $7.9M, full year $27.3M; net loss narrows to $7.2M

## Summary
- Q4 2024 revenue $7.9M (+8% YoY); full year $27.3M, also up 8% from 2023.
- Gross margin 70.3% for Q4 and 70.0% for full year, at high end of 65-70% guidance.
- Net loss improved to $7.2M in Q4 from $22.4M a year ago; full year net loss $47.0M vs $34.5M.
- Diagnostics segment revenue surged 109% YoY in Q4 driven by TRUFORMA and VETGuardian adoption.
- Cash, equivalents and securities $71.4M; adjusted non-GAAP EBITDA loss $20.2M for full year.

## SEC filing metadata
- accession: 0001654954-25-002744
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2025-03-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495425002744/0001654954-25-002744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495425002744/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-002744
- JSON: https://secwatch.observer/filing/0001654954-25-002744.json
- Plain text: https://secwatch.observer/filing/0001654954-25-002744.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.